Affymax (AFFY +8.9%) wins backing from an FDA advisory panel for its peginesatide anemia drug,...

|By:, SA News Editor

Affymax (AFFY +8.9%) wins backing from an FDA advisory panel for its peginesatide anemia drug, which competes with a rival drug from Amgen (AMGN). AFFY shares jumped 20%-plus on Monday when briefing documents related to today's meeting were released; trading has been halted since early this afternoon.